BioSpace News Archive

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results from its second interim efficacy analysis of the ongoing Phase 3 open-label FURI study.

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of solid cancers, today announced that Lewis H. Bender, President and CEO, will be a featured panelist on the “Developments in The Oncology Landscape” panel at East/West CEO.

Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, is scheduled to provide a corporate update at Biotech Showcase 2020.

OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel liquid oral suspension (OS) formulations, announced today that it has received Pre-Investigational New Drug (PIND) acknowledgement from the U.S. Food and Drug Administration (FDA), and has submitted for U.S. patent protection, for the first-ever liquid formulation of quetiapine fumarate

ZAGENO, a leading enterprise marketplace solution connecting e-commerce to life science, today announced that Robert Cruickshank will join the company as chief financial officer, effective January 13.

VBL Therapeutics (Nasdaq: VBLT) today announced the publication of clinical data from the Phase 2 and Phase 3 studies of VB-111 (ofranergene obadenovec) in recurrent glioblastoma (rGBM) in two manuscripts published in the peer-reviewed journal Neuro-Oncology, the official journal of the Society for Neuro-Oncology.

Bio-Path Holdings, Inc. provides an update from several clinical development programs and a 2020 business overview.

Global Blood Therapeutics, Inc. announced that on January 1, 2020, the compensation committee of GBT’s board of directors granted 7 new employees options to purchase an aggregate of 11,200 shares of the company’s common stock with a per share exercise price of $79.49 and restricted stock units for an aggregate of 24,900 shares of the company’s common stock.

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced the appointment of Timothy Compton as chief commercial officer.

Quotient Limited, a commercial-stage diagnostics company, announced the planned appointment of Peter Buhler as Chief Financial Officer, effective as of February 5, 2020.